Skip to main content
. 2020 Sep 15;133(9):441–451. doi: 10.1007/s00508-020-01735-5

Table 1.

Baseline characteristics of all patients treated with PX-104

Safety analysis (n = 12)
Age (years) 50 ± 15
Male 8 (66%)
Comorbidities
Hyperlipidemia 7 (58%)
Arterial hypertension 6 (50%)
Concomitant drug use
Antihypertensive 6 (50%)
Anti-lipidemic 0
Metabolic factors
Glucose (mg/dl) 92 ± 11
Insulin (µU/ml) 16 ± 9
Weight (kg) 89 ± 14.4
Body mass index 29.3 ± 3.6
Systolic blood pressure (mm Hg) 127 ± 14
Diastolic blood pressure (mm Hg) 82 ± 6